• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2022.17060

The fat hepatosis and clinical-metabolic risk factors in adolescent with obesity

[Original research] [Pediatrics]
Vladimir Vladimirovich Bekezin; Korotkaya Natalia; Kozlova Lyudmila V.; Olga Vladimirovna Peresetskaya; Barsukov Alexey V.;

The aim of the study is to determine the contribution of the main clinical and metabolic risk factors of the fatty hepatosis development and its role in the progression of obesity in adolescent. The study included 84 adolescent (12–17 years old) with simple (exogenous-constitutional) obesity using a random sample. It was revealed that the highly sensitive (0.6 and more) risk factors for the development of fatty hepatosis in adolescents include abdominal obesity, insulin resistance, oxidative stress, and highly specific (0.8 and more) risk factors include atherogenic dyslipidemia, hypertriglyceridemia, insulin resistance, pro-inflammatory and prothrombotic statuses, microalbuminuria. In adolescent with obesity and fatty hepatosis, the risk of registering insulin resistance, hypertriglyceridemia, and pro-inflammatory status is increased at 3.48; 8.36 and 3.62 times, respectively. It is recommended, taking into account the personalized risks for adolescents with obesity, to include drugs with hypolipidemic and hepatoprotective activity in the complex therapy at the early stages of fatty hepatosis in order to prevent comorbid pathology in subsequent age periods.

Download

References:
1. Koroy P. V., Slyadnev S. A., Kravchenko Yu. A., Yagoda A. V. Infl uence of metabolic syndrome on course of non-alcoholic fatty liver disease. Terapiya. – Therapy. 2019;5(3):37-42. (In Russ.). https://doi.org/10.18565/therapy.2019.3.37-42
2. Koroy P. V., Slyadnev S. A., Yagoda A. V. Relationship of metabolic syndrome with adhesion molecules in non-alcoholic fatty liver disease. Meditsinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus. 2020;15(1):23-27. (In Russ.). https://doi.org/10.14300/mnnc.2020.15004
3. Mishina E. E., Mayorov A. Yu., Bogomolov P. O., Matsievich M. V., Kokina K. Yu., Bogolyubova A. V. Non-alcoholic fatty liver disease: cause or eff ect of insulin resistance? Saharnyj diabet. – Diabetes mellitus. 2017;20(5):335-342. (In Russ.). https://doi.org/10.14341/DM9372
4. Giulio M., Christopher P. D., Jean-Francois D., Ali C., Valerio N. [et al.]. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64:1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004
5. Meex R. C. R., Watt M. J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 2017;13(9):509-520. https://doi.org/10.1038/nrendo.2017.56
6. Nolan P. B., Carrick-Ranson G., Stinear J. W., Reading S. A., Dalleck L. C. Prevalence of metabolic syndrome and metabolic syndrome components in young adults: a pooled analysis. Prev. Med. Rep. 2017;7:211-215. https://doi.org/10.1016/j.pmedr.2017.07.004
7. Shirokova E. N. Non-alcoholic fatty liver disease, hyperlipidemia and cardiovascular risks. Consilium Medicum. 2017;19(8.2):74-76. (In Russ.). https://doi.org/10.26442/2075-1753_19.8.2.74-76
8. Drapkina O. M., Korneeva O. N. The continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Racional’naya Farmakoterapiya v Kardiologii. – Rational Pharmacotherapy in Cardiology. 2016;12(4):424-429 (In Russ.). https://doi.org/10.20996/1819-6446-2016-12-4-424-429
9. Timakova A. Yu., Skirdenko Yu. P., Livzan M. A., Krolevets T. S., Nikolaev N. A., Nelidova A. V. Cardiovascular comorbidity in non-alcoholic fatty liver disease. Eksperimental’naya i klinicheskaya gastroenterologiya. – Experimental and Clinical Gastroenterology. 2020;182(10):88-95. (In Russ.). https://doi.org/10.31146/1682-8658-ecg-182-10-88-95
10. Vlasov N. N., Kornienko E. A. Non-alcoholic fatty liver disease and metabolic syndrome in childhood. Eksperimental’naya i klinicheskaya gastroenterologiya. – Experimental and Clinical Gastroenterology. 2020;183(11):51-61. (In Russ.). https://doi.org/10.31146/1682-8658-ecg-183-11-51-61
11. Borsukov A. V., Kryukovskij S. B., Pokusaeva V. N., Nikiforovskaya E. N., Peregudov I. V., Morozova T. G. Jelastografija v klinicheskoj gepatologii (chastnye voprosy). Smolensk: Izd. «Smolenskaya gorodskaya tipografiya», 2011. (In Russ.).
12. Musso G., Gambino R., Cassader M., Pagano G. Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Ann. Med. 2011;43:617-649. https://doi.org/10.3109/07853890.2010.518623
13. Ivashkin V. T., Bakulin I. G., Bogomolov P. O., Matsievich M. V., Geyvandova N. I. [et al.]. Results of a multicenter, double-blind, randomized, placebo-controlled post-registration (phase IV) clinical study «Cheetah» (PHG-M2/P02-12), conducted to assess the efficacy and safety of a combined preparation of glycyrrhizic acid and essential phospholipids (Phosphogliv) in non-alcoholic fatty liver disease. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. – Russian journal of gastroenterology, hepatology, coloproctology. 2017;27(2):34-43. (In Russ.). https://doi.org/10.22416/1382-4376-2017-27-2-34-43
14. Zakharova I. N., Malyavskaya S. I., Tvorogova T. M., Vasilyeva S. V., Dmitrieva Yu. A., Pshenichnikova I. I. Metabolic syndrome in children and adolescents. Definition. Diagnostic criteria. Medicinskij sovet. – Medical advice. 2016;16:103-109. (In Russ.). https://doi.org/10.21518/2079-701X-2016-16-103-109
15. Komshilova K. A., Troshina E. A. Obesity and non-alcoholic fatty liver disease: metabolic risks and their correction. Ozhirenie i metabolism. – Obesity and metabolism. 2015;12(2):35-39. (In Russ.). https://doi.org/10.14341/OMET2015235-39__

Keywords: fatty hepatosis, obesity, adolescents, clinical and metabolic risk factors